Montex Swiss has been recognized with the Innovation award in the 2025 Medical Device Network Excellence Awards for its Prolife PX7 Premium device, for its approach to advancing cardiovascular health management through artificial intelligence (AI).
The Medical Device Network Excellence Awards honor the most significant achievements and innovations in the medical devices industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies leading positive change and shaping the future of the industry.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Montex Swiss won the award in the AI: Cardiovascular Monitoring category for introducing advanced artificial intelligence and user-focused features that set new standards in cardiovascular health monitoring.
AI-driven blood pressure measurement: Enhanced speed and comfort while maintaining high accuracy
Traditional blood pressure monitors typically measure during cuff deflation, a process that can be slow and uncomfortable, especially for individuals with hypertension who may require frequent monitoring. The Prolife PX7 Premium introduces a significant advancement by measuring blood pressure during cuff inflation. This approach, enabled by Montex Swiss’s proprietary Prolife AIm technology, reduces measurement time by approximately 1.5 times compared to standard devices and its accuracy is confirmed through clinical validation.
The benefits of this innovation are multifaceted. First, it shortens the duration of each measurement, which is particularly valuable for patients who need to monitor their blood pressure multiple times a day or who experience discomfort during prolonged cuff inflation. Second, the process is less intrusive, minimizing the risk of user movement or anxiety that can compromise measurement accuracy. Additionally, measuring during inflation can help reduce the likelihood of over-inflation, which often causes unnecessary discomfort and can deter users from regular monitoring.
Artificial intelligence further enhances this process by analyzing data from the very first measurement—including blood pressure, heart rate, and atrial fibrillation detection—and using these insights to personalize subsequent readings. For instance, if a user’s initial measurement indicates a tendency toward higher blood pressure or irregular heart rhythms, the device can adjust its algorithms to optimize comfort and accuracy in follow-up measurements. This adaptive approach not only improves clinical reliability but also encourages consistent use by making self-monitoring less burdensome.
Moreover, the device’s intelligent algorithms are designed to minimize common errors such as improper cuff placement or excessive arm movement. Visual indicators and real-time feedback guide users through the process, ensuring that each reading is as accurate and comfortable as possible. By combining speed, comfort, and advanced error reduction features, the Prolife PX7 Premium supports both patient adherence and reliable cardiovascular monitoring outcomes.
Advanced AFIB detection: Early identification of stroke and heart failure risks
Atrial fibrillation (AFIB) is a common but often undiagnosed heart rhythm disorder that significantly increases the risk of stroke and heart failure. Early detection is critical for effective intervention and management. The Prolife PX7 Premium incorporates Prolife AFIB Smart technology, which leverages artificial intelligence to detect AFIB during the inflation phase of blood pressure measurement—a process that enhances both sensitivity and specificity compared to traditional methods.
This real-time detection capability is particularly important for population screening programs, where large numbers of individuals may be assessed in non-clinical settings. By identifying AFIB early—even in asymptomatic individuals—the device supports timely referral for further evaluation and treatment, potentially reducing the incidence of stroke and related complications.
Moreover, the integration of AFIB detection into routine blood pressure monitoring streamlines workflow for clinicians and empowers patients to take a more active role in managing their cardiovascular health. For example, individuals identified as being at risk can share their results directly with healthcare providers via their smartphones, facilitating prompt clinical decision-making regarding medication adjustments or further diagnostic testing.
User-centric design: Intelligent assistance and enhanced usability
Montex Swiss has placed significant emphasis on ensuring that the Prolife PX7 Premium is accessible and easy to use for a wide range of users, including those with limited technical experience or physical challenges. The device features an Intelligent Assistant (IA) that guides users through each step of the measurement process with clear instructions and visual cues. This reduces the likelihood of user error—a common issue with home monitoring devices—and increases confidence in self-measured results.
Critical measurement parameters are displayed both on an extra-large, high-resolution screen and through additional symbols positioned outside the main display area. These visual indicators provide immediate feedback on potential issues such as arm movement or improper cuff placement, allowing users to correct errors before they affect measurement accuracy. The inclusion of risk indicators further enhances safety by alerting users to abnormal readings or potential health risks.
The display itself employs advanced Vertical Alignment (VA) technology for improved clarity and contrast, making it easy to read in various lighting conditions. Night mode functionality and illuminated button areas ensure that users can operate the device comfortably even in low-light environments—a feature particularly beneficial for elderly users or those who need to monitor their blood pressure at night.
The smart conic cuff is designed with user comfort in mind. Its thin, quiet fabric minimizes discomfort during inflation while maintaining durability for long-term use. The cuff’s ergonomic design accommodates a wide range of arm sizes (22-45 cm), ensuring accurate readings across diverse patient populations.
“Over 6 million people die from stroke each year. Two major, often silent risk factors are high blood pressure and atrial fibrillation. Public screenings help detect these early and guide people toward care. At Prolife, we offer a compact device that checks both conditions in one step. But meaningful change only happens when we join forces. We bring technology and experience. You, the doctors, bring local insight and leadership. Let’s collaborate—to make early detection routine and save lives together.”
– Gerhard Frick, Montex Swiss AG, Clinical Application, Member of the AAMI/ESH/ISO Joint Working Group “Non-invasive Sphygmomanometers”
Company Profile
Montex Swiss AG has been successfully operating in global markets since 2007. The company’s key specialists and top managers are world-class experts with over 20 years of experience in the development, standardization, and promotion of medical devices and health care products. All devices are created as a result of extensive research conducted in close collaboration with physicians and leading validation centers across Europe. This approach ensures the highest levels of accuracy, reliability, and compliance with international standards.
One of the company’s leading brands is Prolife — a revolutionary brand that develops reliable medical devices for home health monitoring. At the core of Prolife products are clinically proven effectiveness, advanced technology, and Swiss quality.
The company’s mission is to create and apply cutting-edge technologies to improve the quality of personal life.
Its blood pressure monitors, nebulizers, and thermometers are developed with meticulous attention to detail, ensuring measurement accuracy, ergonomic design, and compliance with international regulations. Each Prolife device is carefully tested to ensure it meets the highest standards and goes beyond what users expect.
What makes Prolife unique?
• Swiss Quality: Montex Swiss’s products prioritize accuracy, reliability, and durability.
• Innovative Technology: Advanced technologies ensure our devices meet the highest medical standards.
• Clinical Validation: Ensures the accuracy and reliability of our medical devices, validated by independent studies.
• Trust: Prolife products are trusted in dozens of countries, with positive feedback from both professionals and consumers.
Contact Details
Montex Swiss AG, Tramstrasse 16, CH-9442 Berneck, Switzerland
E-mail: info@montex.ch
Links
Website: https://www.prolife-health.com/
